Archive: March/April 2025
Advances in LLM
Is There a New Standard-of-Care Therapy for Advanced Hodgkin Lymphoma?
H&O What has been the traditional treatment for patients with advanced Hodgkin lymphoma? AH The traditional treatment for patients with stage III or IV Hodgkin lymphoma […]
Breast Cancer
Management of Toxicities From Antibody-Drug Conjugates
H&O Which antibody-drug conjugates (ADCs) are approved for use in breast cancer? HR The first ADC to be approved for use in breast cancer was trastuzumab […]
Feature Article
Targeting RAS in Gastrointestinal Malignancies
Abstract: Kirsten rat sarcoma virus (KRAS) is one of the prevalent oncogenic drivers in gastrointestinal (GI) cancers, including pancreatic ductal adenocarcinoma and colorectal cancer. The KRAS […]
Feature Article
Update on PARP Inhibitors for the Treatment of Ovarian Cancer
Abstract: Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors (PARPis) were first granted US Food and Drug Administration (FDA) approval for ovarian cancer. Trials have focused on high-grade serous […]
Prostate Cancer In Focus
PARP Inhibition in HRR Gene–Mutated Metastatic Castration-Resistant Prostate Cancer
H&O What role do mutations in homologous recombination repair (HRR) genes play in metastatic castration-resistant prostate cancer (mCRPC)? TD We have recently come to realize that […]
Advances in Hematology
Thrombosis in Immune Thrombocytopenia
H&O What is immune thrombocytopenia (ITP), and what causes it? HL ITP is an autoimmune disorder that causes a significant decrease in the blood platelet count, […]
Advances in Drug Development
Ethics in Medicine: Avoiding Conflicts of Interest in Prescribing
H&O What are some potential sources of conflict of interest that physicians may encounter in prescribing? GVN The main conflict of interest is the one that […]
CLL
The Use of Fixed-Dose Regimens in Chronic Lymphocytic Leukemia
H&O What fixed-dose regimens are in use in chronic lymphocytic leukemia (CLL)? AK Fixed-duration regimens have been used for a long time in patients with CLL. […]
Letter From the Editor
Letter From the Editor: A Common Cause
Practicing in Durham, North Carolina, I have the privilege of caring for a wide range of patients—Black and White, old and young, rich and poor. People […]